medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (5)


Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients

Abdel-Rahman Z, El-Kassas M, Saad Y, Bahnassy A, Seif El-Din HKS, Darweesh SK, Abdel HH, Esmat G

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 774-781
Archivo PDF: 169.06 Kb.


RESUMEN

sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dienstag JL MJ. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterol 2006; 130: 225-30.

  2. Motola-Kuba D, Zamora-Valdés D UM. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16-24.

  3. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid MGF, SM. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatol 2000; 32: 111-5.

  4. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Deviation 2000; 14: 1027-47.

  5. Chu ZL, Pio F, Welsh K. A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis. J Biol Chem 2001; 276: 9239-45.

  6. Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA. Caspase recruitment domain containing protein 15 mutations in patients with colorectal cancer. Can Res 2006; 66: 2532-5.

  7. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 2000; 18: 621-63.

  8. Jihua CH, Xisheng L, Shengli C, Zongxian C, Guang C, Jirun PS, DW and R. BCL10 gene mutation in Hepatocellular carcinoma. J Chin Med 2001; 114: 747–51.

  9. Wang M, Qanungo SCM. apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei. FEBS 2005; 579: 2411-5.

  10. McConnell BB, Vertino PM. Activation of Caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. Can Res 2000; 60: 6243-7.

  11. Ishak K, Baptista ABL. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  12. Bruix J, Boix LSM. Focus on hepatocellular carcinoma. Can Cell 2004; 5: 215-9.

  13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona- 2000 EASL conference. J Hepatol 2001; 35: 421-30.

  14. Salomao M, McMillen E, Lefkowitch JH. Recent advances in the classification of hepatocellular carcinoma. Diagnostic Histopathology 2012; 18: 37-45.

  15. Zekri AR, Hassan ZK, Bahnassy AA, Sherif GM, Eldahshan D, Abouelhoda M, Ali A HM. Molecular Prognostic Profile of Egyptian HCC Cases Infected with Hepatitis C Virus. Asian Pas J Cancer Prev 2012; 13: 5433-8.

  16. Nakamura S, Nakamura SMT. Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma. Can 2005; 104: 1885-1193.

  17. Soung YH, Lee JW KS. Mutational analysis of proapoptotic caspase-9 gene in common human carcinomas. APMIS 2006; 114: 292-7.

  18. Park JY, Park JM JJ. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 2006; 15: 1963-71.

  19. Hosgood HD, Baris DZY. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008; 26: 148-51.

  20. Qiu B, Wang X, Zhang P, Shi C, Zhang J, Qiu W, Wang W, et al. Association of TNF-a promoter polymorphism with the outcome of persistent HBV infection in a northeast Chinese Han population. Act Biochim Biophys Sin(Shanghai) 2012; 44: 712-8.

  21. Kischkel FC, Lawrence DA TA. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276: 46639-46.

  22. Proell M, Gerlic M, Mace PD, Reed JC, Riedl SJ. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem J 2013; 449: 613-21.

  23. Walter SR, Thein HH GH. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C. J Hepatol Gastroenterol 2011; 10: 1440-6.

  24. Soliman A, Hung CH TA. Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt. Int J Hepatol 2010; 4: 681-90.

  25. Abdel-Wahab M, El-Ghawalby N MM. Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center. Hepatogastroenterology 2007; 54: 157-62.

  26. Mummadi RR, Petersen JR XS. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16: 5705-10.

  27. Yu MC, Chan KM LC. Alkaline Phosphatase: Does it have a Role in Predicting Hepatocellular Carcinoma Recurrence. World J Gastrointest Surg 2011; 15: 1440-9.

  28. Chen TM, Huang PT TM. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Gastroenterol Hepatol 2007; 22: 669-75.




2020     |     www.medigraphic.com